FM (chemotherapy)
(Redirected from FM-R)
FM in the context of chemotherapy means a chemotherapy regimen used as first-line therapy in indolent lymphomas. In combination with rituximab it is called R-FM or RFM or FM-R or FMR.
The [R]-FM regimen consists of:
- Rituximab - an anti-CD20 monoclonal antibody that is able to kill both normal B cells and malignant ones;
- Fludarabine - an antimetabolite;
- Mitoxantrone - a synthetic anthracycline analogue (an anthraquinone) that is able to intercalate DNA and prevent mitosis.[1]
This regimen is also sometimes used in some autoimmune disorders that are inherently sensitive to rituximab, fludarabine and mitoxantrone in monotherapies (e.g. multiple sclerosis).
Dosing regimen
[edit]| Drug | Dose | Mode | Days |
|---|---|---|---|
| Rituximab | 375 mg/m2 | IV infusion | Day 1 |
| Fludarabine | 25 mg/m2 | IV infusion | Days 1-3 |
| Mitoxantrone | 10 mg/m2 | IV infusion | Day 1 |